BMS

Showing 15 posts of 286 posts found.

yervoy image

NICE hails ‘breakthrough’ skin cancer treatments

November 2, 2012
Sales and Marketing BMS, NICE, Roche, Yervoy, Zelboraf

Two new skin cancer drugs have been recommended by NICE, which hailed the drugs as ‘breakthrough treatments’. Bristol-Myers Squibb’s Yervoy …

BMS image

Patent losses force change for Sanofi

October 3, 2012
Sales and Marketing Avapro, BMS, Plavix, Sanofi, patent loss

Patent expiries are behind the decision by Sanofi and Bristol-Myers Squibb to radically restructure their long-term corporate alliance. The loss …

yervoy image

BMS highlights Yervoy survival data

October 1, 2012
Research and Development, Sales and Marketing BMS, Roche, Yervoy, Zelboraf

Bristol-Myers Squibb’s melanoma drug Yervoy helps patients survive for longer than if they are receiving standard chemotherapy alone, according to …

Eliquis image

Eliquis receives nod in AF

September 24, 2012
Sales and Marketing BMS, CHMP, Eliquis, Pfizer, Pradaxa, Xarelto

Bristol-Myers Squibb and Pfizer have received a boost with the CHMP’s recommendation that their co-marketed oral anticoagulant Eliquis should gain …

Patient death halts BMS hep C trial

August 30, 2012
Sales and Marketing BMS, HCV, hepatitis C

Bristol-Myers Squibb has admitted that the death of a patient was behind its decision to stop development of a potential …

Zelboraf image

NICE still minded not to recommend Zelboraf

August 9, 2012
Sales and Marketing BMS, NICE, QALY, Yervoy, Zelboraf

NICE is asking Roche for more information about its melanoma pill Zelboraf, saying it is still too expensive and its …

Bristol-Myers Squibb halts Hep C pill study

August 2, 2012
Research and Development, Sales and Marketing BMS, hepatitis C, pill, trial suspension

Bristol-Myers Squibb has halted a mid-stage trial of a new Hepatitis C drug due to major safety concerns. In a …

BMS image

BMS unveils $165m expansion in Puerto Rico

July 17, 2012
Manufacturing and Production BMS, Puerto Rico, diabetes, manufacturing

A facility operated by Bristol-Myers Squibb in Puerto Rico stands to benefit from a $165 million investment programme that will …

AZ image

AstraZeneca and BMS buy Amylin for $7 billion

July 2, 2012
Sales and Marketing Amylin, AstraZeneca, BMS

AstraZeneca and Bristol-Myers Squibb have struck a deal to purchase diabetes specialist Amylin in a complicated agreement worth $7 billion. …

Eliquis image

FDA delays Eliquis approval

June 26, 2012
Sales and Marketing BMS, Eliquis, FDA, Pfizer, Xarelto

The FDA has asked Pfizer and Bristol-Myers Squibb for more information about its key blood thinner Eliquis. The US regulator …

BMS invests $15 million in Asian diabetes programme

June 11, 2012
Sales and Marketing Asia, BMS, China, India, Onglyza, diabetes

Bristol-Myers Squibb has invested $15 million into its ‘Together on Diabetes’ campaign in India and China. Together on Diabetes is …

Plavix loses US patent protection

May 18, 2012
Sales and Marketing BMS, FDA, Lipitor, Pfizer, Plavix, Sanofi

Sanofi and Bristol-Myers Squibb’s blood thinner Plavix has lost its patent protection in the US.  The drug, which made $6.6 …

yervoy image

Scottish watchdog rejects Yervoy

May 14, 2012
Sales and Marketing BMS, Cancer, NICE, SMC, Yervoy, melanoma

The Scottish Medicines Consortium is not recommending Bristol-Myers Squibb’s melanoma treatment Yervoy.  The SMC said that Yervoy (ipilimumab), which has …

New Quad HIV pill on track for FDA approval

May 14, 2012
Research and Development, Sales and Marketing BMS, Compera, FDA, Gilead, HIV, The Quad

Gilead Sciences’ four-in-one HIV pill has been given the thumbs up by an FDA advisory group.  The US regulator is …

dr_jeremy_levin_web_only

Teva appoints new president and chief executive

May 10, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Jeremy Levin, Teva

Ex-BMS head Dr Jeremy Levin has been appointed president and chief executive of Teva.  Prior to joining Teva, Levin, who …

The Gateway to Local Adoption Series

Latest content